IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
IGC Pharma announced that its Phase 2 CALMA trial for IGC-AD1 has reached the previously disclosed enrollment target of 146 patients, with all participants randomized at baseline. The company plans to continue limited over-enrollment to account for potential attrition and ensure a robust evaluable population for the upcoming topline analysis.
Key figures
- Drug Name
- IGC-AD1
- Phase Of Trial
- Phase 2
- Enrollment target
- 146
- Patients randomized
- 146
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.